ASP Isotopes (ASPI) Q4 2024 earnings summary

Executive summary

• Three manufacturing plants commenced commercial production, including Carbon-14, Silicon-28, and Ytterbium-176, overcoming technical challenges during commissioning.

• PET Labs generated $4.2 million in revenue for the year, with expectations for growth due to recent investments and increased capacity.

• Successful enrichment of Ytterbium-176 was announced, with commercial samples now being produced.

Financial highlights

• PET Labs reported $4.2 million in annual revenue, with stable performance and anticipated growth.

• Carbon-14 plant secured a take-or-pay contract for a minimum of $2.5 million per year, with potential for higher sales.

• Ytterbium-176 pricing discussions are around $20,000 per gram, with indicated demand for two kilograms.

• Silicon-28 orders are expected to increase, with ongoing discussions with multiple customers.

• Operating cash flow burn was $15 million last year, with $60 million in cash on hand at year-end.

Outlook and guidance

• No formal revenue or earnings guidance provided for 2025.

• Free cash flow positive status anticipated in the second half of the year, based on current contracts and operating expenses.

• Plans to ramp up ytterbium production and expand enrichment facilities in South Africa, Iceland, and potentially North America.

• Construction of new plants (Nickel-64, Gadolinium-160, Lithium-6) expected to begin later this year, pending permit approvals.